Community Oncology Conference

Let's Rebuild 340B as a Patient-Centric Model, ACCC Executive Director Recommends

April 29, 2017

Christian G. Downs, JD, MHA, discusses his thoughts on how rebuilding the 340B program should be addressed, Medicare Payment Advisory Commission’s Part B cost control proposals, and the potential for progress in tackling rising drug costs.

Pharmacists Employ New Strategies for Orals Adherence

April 29, 2017

Keeping patients on their oral oncology medications involves a combination of active management, record keeping, and coordination among healthcare workers, pharmacy professionals explained during a panel discussion.

How Cabozantinib is Being Used in Practice for Patients With RCC

April 28, 2017

Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).

Staff Acceptance Was Big Hurdle in OCM Adoption

April 28, 2017

Speakers at the 2017 Community Oncology Alliance (COA) annual meeting in National Harbor, Maryland, reflect on challenges in the first year of the OCM.

Genetic Testing Worth the Time, Effort, and Money, Burris Says

April 28, 2017

The molecular profile of a patient with cancer who is about to be treated for their metastatic disease is the most critical piece of information you can have for that patient, according to Howard A. “Skip” Burris III, MD.

ACCC Health Policy Director Addresses ACA Repeal, MedPAC's Part B Recommendations

April 28, 2017

Leah Ralph discusses the ACCC’s position on the ACA repeal bill, the Medicare Payment Advisory Commission’s (MedPAC) Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.

PBMs Extend Encroachment Into Physician Dispensing

April 27, 2017

An April report from COA stated that PBMs have been calling patients and urging them to get their drugs from PBM-owned pharmacy networks, rather than through physician dispensaries. At this year’s Community Oncology Conference, presentations and discussions focused on this report.

How Oral Targeted Therapies and IV Immunotherapies Disrupted Community Practice Financing

April 27, 2017

Barbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.